Literature DB >> 11051265

Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.

I Petak1, L Douglas, D M Tillman, R Vernes, J A Houghton.   

Abstract

Seven pediatric rhabdomyosarcoma (RMS) cell lines were resistant to the induction of apoptosis via the Fas death receptor. In contrast, four of seven lines (RD, Rh1, Rh18, and Rh30) were highly sensitive to tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL). TRAIL induced apoptosis within 4 h and also reduced clonogenic survival, both reversible by caspase inhibitors. DR5 (but not DR4) was expressed at high level in all cell lines. Expression of the decoy receptors DcR1 and DcR2 did not correlate with TRAIL sensitivity. All RMS lines expressed the adapter molecule FADD, and six of seven expressed procaspase-8. Expression of the inhibitory proteins c-FLIPL and c-FLIPs was high in three TRAIL-sensitive (RD, Rh1, and Rh30) and two TRAIL-resistant (Rh28 and Rh41) lines. All RMS lines expressed Bid and procaspases-3, -6, -7, and -9. Procaspases-8 and -10 were highest in TRAIL-sensitive RMS (RD, Rh1, and Rh30), and procaspase-10 was not expressed in Rh18, Rh36, or Rh41. TRAIL induced loss of mitochondrial membrane potential in TRAIL-sensitive Rh1 but not in TRAIL-resistant Rh41 cells. There was no correlation between expression of members of the Bcl-2 family (Bcl-2, Bcl-xL, Bax, and Bak) and TRAIL sensitivity. TRAIL-sensitive Rh18 expressed procaspase-8 in the absence of procaspase-10 and c-FLIP, and procaspase-10 was not detected in TRAIL-resistant Rh41 in the presence of procaspase-8 and c-FLIP. Data suggest that caspase-8 may be sufficient to deliver the TRAIL-induced apoptotic signal in the absence of both caspase-10 and c-FLIP (Rh18) but not in the presence of c-FLIP (Rh41). In RD, Rh1, and Rh30, the presence of c-FLIP may require amplification of the apoptotic signal via caspase-10.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051265

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Targeting death receptors: is this trail still hot?

Authors:  Rajen Mody
Journal:  Transl Pediatr       Date:  2013-04

3.  Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro.

Authors:  Helga Barti-Juhasz; Rudolf Mihalik; Katalin Nagy; Giulia Grisendi; Massimo Dominici; Istvan Petak
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

4.  Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Aditi S Iyengar; Jacob M Loupe; Andrew D Hollenbach
Journal:  Int J Biochem Cell Biol       Date:  2011-03-31       Impact factor: 5.085

5.  Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines.

Authors:  Takehiro Matsuda; Alex Almasan; Mariko Tomita; Jun-nosuke Uchihara; Masato Masuda; Kazuiku Ohshiro; Nobuyuki Takasu; Hideo Yagita; Takao Ohta; Naoki Mori
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.

Authors:  Katalin Nagy; Kinga Székely-Szüts; Kamel Izeradjene; Leslie Douglas; Mike Tillman; Helga Barti-Juhász; Massimo Dominici; Carlotta Spano; Gian Luca Cervo; Pierfranco Conte; Janet A Houghton; Rudolf Mihalik; László Kopper; István Peták
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

7.  Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner.

Authors:  Ingo H Engels; Gudrun Totzke; Ute Fischer; Klaus Schulze-Osthoff; Reiner U Jänicke
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

Review 8.  Apoptotic pathways as a therapeutic target for colorectal cancer treatment.

Authors:  Aman M Abraha; Ezra B Ketema
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

9.  Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Authors:  Kevin N Dietz; Patrick J Miller; Andrew D Hollenbach
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

10.  Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

Authors:  Melinda S Merchant; James I Geller; Kristin Baird; Alexander J Chou; Susana Galli; Ava Charles; Martha Amaoko; Eunice H Rhee; Anita Price; Leonard H Wexler; Paul A Meyers; Brigitte C Widemann; Maria Tsokos; Crystal L Mackall
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.